Outset Medical, Inc. ( (OM) ) has released its Q2 earnings. Here is a breakdown of the information Outset Medical, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Outset Medical, Inc. is a medical technology company that has developed the Tablo Hemodialysis System, a pioneering technology designed to simplify and reduce the costs associated with dialysis, serving both hospital and home settings.
In its second-quarter earnings report for 2025, Outset Medical highlighted a strong performance with a notable increase in revenue and a reduction in operating expenses. The company has raised its revenue guidance for the year, reflecting confidence in its growth trajectory.
The company reported a 15% increase in net revenue to $31.4 million, driven by a 25% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services also grew by 11%. Outset Medical achieved a gross margin of 37.8%, marking an improvement from the previous year. Operating expenses were significantly reduced by nearly 30%, contributing to a decrease in net loss from $34.5 million in 2024 to $18.5 million in 2025.
Outset Medical’s strategic moves, including a new enterprise agreement with a major national health system, have expanded Tablo’s presence to over 900 sites in the U.S. The company continues to focus on expanding its market reach and improving its financial performance.
Looking ahead, Outset Medical remains optimistic about its growth prospects, with management expecting continued revenue growth and further improvements in profitability as they advance towards achieving near-term profitability goals.